The incidence of cardiogenic shock in community studies has not decreased significantly over time. Despite decreasing mortality rates associated with increasing utilisation of revascularisation, shock remains the leading cause of death for patients hospitalised with acute myocardial infarction (MI). Although shock often develops early after MI onset, it is typically not diagnosed on hospital pr...

The incidence of cardiogenic shock in community studies has not decreased significantly over time. Despite decreasing mortality rates associated with increasing utilisation of revascularisation, shock remains the leading cause of death for patients hospitalised with acute myocardial infarction (MI). Although shock often develops early after MI onset, it is typically not diagnosed on hospital pr...

We read with interest the article by Ceglarek et al.1 recently published in European Heart Journal. The authors described, from a prospective cohort including 458 patients admitted for cardiogenic shock (CS) complicating acute myocardial infarction (AMI), new routinely available biomarker-based risk score called CLIP [acronym of cystatin C, lactate, interleukin-6 and N-terminal pro B-type natri...

BACKGROUND Shock is a life-threatening condition in emergency departments (EDs) and is associated with a high mortality; however, its clinical characteristics and current interventions in China are seldom reported. This study investigated the clinical characteristics and current interventions of shock patients in Chinese EDs. METHODS This multicenter prospective cohort study was conducted in ...

OBJECTIVES This study sought to evaluate 30-day all-cause mortality of patients treated with primary percutaneous coronary intervention (PCI) presenting with an acute myocardial infarction (AMI) due to an unprotected left main coronary artery (ULMCA) culprit lesion. In addition, an average estimated mortality rate was extrapolated from the available data. BACKGROUND There are limited data ava...

Background: Consensus guidelines and expert recommendations suggest that either dopamine or norepinephrine can be used in the treatment of shock, but few randomized trials exist. Objective: To compare dopamine to norepinephrine as first-line vasopressor therapy in the treatment of shock. Design: Multicenter randomized head-to-head trial. Participants/Methods: In multiple European centers patien...

BACKGROUND The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock. METHODS Patients with shock due to left ventricular failure complicating myocardial infarction were randomly assigned to emergency revascularization (152 patients) or initial...